Basking Ridge, NJ – According to filings with the U.S. Securities and Exchange Commission, Caladrius Biosciences is raising $2,432,437.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, David Mazzo played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Caladrius Biosciences

Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, cardiovascular disease. We are developing a first- in-class cell therapy product that is based on the notion that our body contains finely tuned mechanisms for self-repair. Our technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication.

To learn more about Caladrius Biosciences, visit http://www.caladrius.com/

Contact:
David Mazzo, President and Chief Executive Officer
908-842-0100
dmazzo@caladrius.com
https://www.linkedin.com/in/david-mazzo-76b13912/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved